Oncotarget

Research Papers:

Therapeutic effects of umbilical cord blood plasma in a rat model of acute ischemic stroke

Jongman Yoo, Han-Soo Kim, Jin-Ju Seo, Jang-Hyoun Eom, Seong-Mi Choi, Sanghyun Park, Dong-Wook Kim and Dong-Youn Hwang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:79131-79140. https://doi.org/10.18632/oncotarget.12998

Metrics: PDF 908 views  |   HTML 1454 views  |   ?  


Abstract

Jongman Yoo1,*, Han-Soo Kim2,*, Jin-Ju Seo3, Jang-Hyoun Eom3, Seong-Mi Choi4, Sanghyun Park4, Dong-Wook Kim4, Dong-Youn Hwang1,3

1Department of Microbiology and Institute of Basic Medical Sciences, School of Medicine, CHA University, Seongnam, Kyeonggido 463-400, Korea

2Department of Biomedical Sciences, Catholic Kwandong University, Gangneungsi, Gangwondo 210-701, Korea

3Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Kyeonggido 463-400, Korea

4Department of Physiology and Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine, Seoul 120-752, Korea

*These authors contributed equally to this work

Correspondence to:

Dong-Wook Kim, email: dwkim2@yuhs.ac

Dong-Youn Hwang, email: hdy@cha.ac.kr

Keywords: stroke, umbilical cord plasma, ischemia, neuroinflammation, neurogenesis

Received: September 20, 2016     Accepted: October 24, 2016     Published: October 31, 2016

ABSTRACT

Umbilical cord blood plasma (UCB-PL) contains various cytokines, growth factors, and immune modulatory factors that regulate the proliferation and function of immune cells and adult stem cells. Despite its therapeutic potential, the effects of UCB-PL treatment in conditions of ischemic brain injury have yet to be investigated. In this study, we demonstrated that both behavioral and structural impairments resulting from ischemic brain injury were significantly prevented/reversed after intravenous administration of UCB-PL relative to the vehicle control. As early as 1-week post-ischemia, an increased number of newborn cells in the subventricular zone and a reduced number of activated microglial cells in the peri-infarct area were observed in the UCB-PL group, suggesting that enhanced neurogenesis and/or the suppression of inflammation may have contributed to functional protection/recovery. Moreover, UCB-PL was more effective than plasma derived from a 65-year-old healthy adult for the treatment of ischemia-related structural and functional deficits, indicating that UCB-PL had greater therapeutic potential. This study provides valuable insights into the development of a safe, effective, and cell-free strategy for the treatment of ischemic brain damage and a much-needed alternative for patients who are ineligible for thrombolytic therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12998